Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free DWTX Stock Alerts

Dogwood Therapeutics (DWTX) Financials

Dogwood Therapeutics logo
$1.37 -0.07 (-4.86%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$1.43 +0.06 (+4.38%)
As of 07/16/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Dogwood Therapeutics

Annual Income Statements for Dogwood Therapeutics

This table shows Dogwood Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -10 -16 -12 -5.30 -13 -36
Consolidated Net Income / (Loss)		 -10 -16 -12 -5.30 -12 -34
Net Income / (Loss) Continuing Operations		 -10 -16 -12 -5.30 -12 -34
Total Pre-Tax Income 		-10 -16 -12 -5.30 -12 -34
Total Operating Income		 -10 -16 -12 -5.45 -12 -28
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 10 16 12 5.45 12 28
Selling, General & Admin Expense		 9.81 4.85 4.25 3.72 8.70 6.10
Research & Development Expense		 0.19 11 8.07 1.73 3.53 22
Other Special Charges / (Income)		 - - - - 0.00 0.00
Total Other Income / (Expense), net		 -0.34 -0.31 0.13 0.15 -0.12 -6.07
Interest Expense		 0.38 -0.01 -0.07 - 0.00 6.13
Interest & Investment Income		 - - - 0.15 -0.09 0.10
Other Income / (Expense), net		 0.04 -0.32 0.07 0.00 -0.03 -0.03
Income Tax Expense		 - - - 0.00 -0.00 0.22
Preferred Stock Dividends Declared		 - - - - 0.51 1.26
Basic Earnings per Share		 ($2.10) ($1.92) ($1.11) ($7.05) ($12.52) ($7.13)
Weighted Average Basic Shares Outstanding		 4.93M 8.33M 11.07M 751.07K 1.03M 4.98M
Diluted Earnings per Share		 ($2.10) ($1.92) ($1.11) ($7.05) ($12.52) ($7.13)
Weighted Average Diluted Shares Outstanding		 4.93M 8.33M 11.07M 751.07K 1.03M 4.98M
Weighted Average Basic & Diluted Shares Outstanding		 - 8.33M 18.33M 19.26M 1.91M 33.40M

Quarterly Income Statements for Dogwood Therapeutics

This table shows Dogwood Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.24 -1.10 -1.29 -1.05 -2.28 -8.24 -12 -3.81 -16 -3.78 -4.99
Consolidated Net Income / (Loss)		 -1.24 -1.10 -1.29 -1.05 -2.28 -7.73 -11 -3.81 -16 -3.78 -4.99
Net Income / (Loss) Continuing Operations		 -1.24 -1.10 -1.29 -1.05 -2.28 -7.73 -11 -3.81 -16 -3.78 -4.99
Total Pre-Tax Income 		-1.24 -1.10 -1.29 -1.05 -2.28 -7.73 -11 -3.81 -16 -3.75 -4.99
Total Operating Income		 -1.27 -1.14 -1.31 -1.07 -2.30 -7.54 -4.43 -3.92 -16 -3.81 -5.08
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 1.27 1.14 1.31 1.07 2.30 7.54 4.43 3.92 16 3.81 5.08
Selling, General & Admin Expense		 0.90 0.84 0.97 0.73 1.77 5.23 1.99 1.35 1.29 1.47 2.41
Research & Development Expense		 0.37 0.30 0.34 0.34 0.54 2.32 2.44 2.57 15 2.34 2.67
Total Other Income / (Expense), net		 0.04 0.03 0.02 0.02 0.02 -0.19 -6.30 0.12 0.06 0.06 0.07
Interest Expense		 - - 0.00 0.00 0.00 - 6.13 0.00 0.00 - 0.00
Interest & Investment Income		 0.04 - 0.02 0.02 0.02 -0.16 -0.15 0.11 0.08 0.05 0.08
Other Income / (Expense), net		 - - 0.00 0.00 0.00 -0.03 -0.02 0.00 -0.02 0.01 -0.01
Income Tax Expense		 - - 0.00 0.00 0.00 -0.00 0.19 0.00 -0.00 0.03 0.00
Basic Earnings per Share		 ($1.62) ($1.47) ($1.68) ($1.15) ($2.05) ($8.02) ($8.45) ($1.99) ($8.20) ($0.76) ($0.15)
Weighted Average Basic Shares Outstanding		 763.75K 751.07K 770.32K 916.03K 1.11M 1.03M 1.44M 1.91M 1.92M 4.98M 33.54M
Diluted Earnings per Share		 ($1.62) ($1.47) ($1.68) ($1.15) ($2.05) ($8.02) ($8.45) ($1.99) ($8.20) ($0.76) ($0.15)
Weighted Average Diluted Shares Outstanding		 763.75K 751.07K 770.32K 916.03K 1.11M 1.03M 1.44M 1.91M 1.92M 4.98M 33.54M
Weighted Average Basic & Diluted Shares Outstanding		 19.26M 19.26M 19.26M 27.76M 1.33M 1.91M 1.91M 1.91M 2.29M 33.40M 33.63M

Annual Cash Flow Statements for Dogwood Therapeutics

This table details how cash moves in and out of Dogwood Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 29 -16 -6.98 -3.71 12 -8.33
Net Cash From Operating Activities		 -3.90 -16 -11 -4.87 -8.79 -16
Net Cash From Continuing Operating Activities		 -3.90 -16 -11 -4.87 -8.79 -16
Net Income / (Loss) Continuing Operations		 -10 -16 -12 -5.30 -12 -34
Consolidated Net Income / (Loss)		 -10 -16 -12 -5.30 -12 -34
Depreciation Expense		 - - - 0.00 0.01 0.00
Amortization Expense		 0.05 - - 0.00 0.06 0.05
Non-Cash Adjustments To Reconcile Net Income		 7.37 0.32 0.58 0.62 4.07 18
Changes in Operating Assets and Liabilities, net		 -0.97 -0.05 0.20 -0.19 -0.58 0.09
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 3.76 0.00
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 3.76 0.00
Divestitures		 - - - 0.00 3.76 0.00
Net Cash From Financing Activities		 33 -0.10 4.49 1.16 17 7.28
Net Cash From Continuing Financing Activities		 33 -0.10 4.49 1.16 17 7.28
Repurchase of Common Equity		 - - 0.00 - 0.00 -0.05
Issuance of Debt		 1.99 - - 0.00 15 3.00
Issuance of Common Equity		 31 -0.30 4.49 0.00 1.38 4.25
Other Financing Activities, net		 0.18 0.20 - 1.16 -0.00 0.09

Quarterly Cash Flow Statements for Dogwood Therapeutics

This table details how cash moves in and out of Dogwood Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.20 -1.47 -0.94 0.64 -0.98 13 2.69 -4.15 -3.27 -3.60 6.70
Net Cash From Operating Activities		 -0.96 -1.47 -0.94 -0.81 -0.91 -6.13 -4.68 -4.03 -3.27 -3.64 -4.59
Net Cash From Continuing Operating Activities		 -0.96 -1.47 -0.94 -0.81 -0.91 -6.13 -4.68 -4.03 -3.27 -3.64 -4.63
Net Income / (Loss) Continuing Operations		 -1.24 -1.10 -1.29 -1.05 -2.28 -7.73 -11 -3.81 -16 -3.78 -4.99
Consolidated Net Income / (Loss)		 -1.24 -1.10 -1.29 -1.05 -2.28 -7.73 -11 -3.81 -16 -3.78 -4.99
Depreciation Expense		 - - 0.00 - - 0.01 0.02 0.02 -0.03 - 0.00
Amortization Expense		 - - 0.00 - - 0.06 0.05 - - - 0.00
Non-Cash Adjustments To Reconcile Net Income		 0.15 0.15 0.14 0.15 0.09 3.69 6.23 0.06 12 0.07 0.47
Changes in Operating Assets and Liabilities, net		 0.13 -0.51 0.21 0.09 1.28 -2.16 -0.05 -0.30 0.55 0.08 -0.11
Net Cash From Investing Activities		 - - 0.00 - - 3.76 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - 3.76 0.00 - - - 0.00
Net Cash From Financing Activities		 1.16 - 0.00 1.45 -0.07 15 7.37 -0.12 - 0.03 11
Net Cash From Continuing Financing Activities		 1.16 - 0.00 1.45 -0.07 15 7.37 -0.12 - 0.03 11
Repurchase of Common Equity		 - - - - - - 0.00 - - - -0.11
Issuance of Debt		 - - 0.00 - - 15 3.00 - - - 0.00
Other Financing Activities, net		 - - 0.00 1.45 -0.07 -1.38 4.37 -0.12 - -4.17 11
Effect of Exchange Rate Changes		 - - 0.00 - - - 0.00 0.01 - - -0.00

Annual Balance Sheets for Dogwood Therapeutics

This table presents Dogwood Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 31 16 8.37 4.17 94 90
Total Current Assets		 31 16 8.37 4.17 17 8.43
Cash & Equivalents		 30 14 7.03 3.32 15 6.52
Prepaid Expenses		 1.68 1.77 1.34 0.85 1.70 1.91
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.02 0.01
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 78 82
Goodwill		 - - - 0.00 12 12
Intangible Assets		 - - - 0.00 66 69
Other Noncurrent Operating Assets		 - - - 0.00 0.22 0.18
Other Noncurrent Nonoperating Assets		 - - - - 0.00 0.16
Total Liabilities & Shareholders' Equity		 31 16 8.37 4.17 94 90
Total Liabilities		 1.53 1.28 1.04 0.36 30 15
Total Current Liabilities		 1.53 1.28 1.04 0.36 3.18 3.06
Accounts Payable		 0.37 0.35 0.57 0.11 1.23 0.76
Accrued Expenses		 1.16 0.92 0.47 0.25 1.89 2.24
Current Deferred Revenue		 - - - - - 0.00
Other Current Liabilities		 - - - 0.00 0.05 0.06
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 27 12
Noncurrent Deferred Revenue		 - - - - - 0.00
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - 0.00 11 12
Other Noncurrent Operating Liabilities		 - - - 0.00 16 0.11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - 0.00 74 0.00
Total Equity & Noncontrolling Interests		 30 15 7.33 3.81 -10 75
Total Preferred & Common Equity		 30 15 7.33 3.81 -10 75
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 30 15 7.33 3.81 -10 75
Common Stock		 58 58 63 66 68 184
Retained Earnings		 -28 -44 -56 -61 -74 -108
Treasury Stock		 - - 0.00 -0.30 -0.30 -0.30
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 -3.86 -0.59

Quarterly Balance Sheets for Dogwood Therapeutics

This table presents Dogwood Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5.25 3.22 3.64 2.28 97 97 92 95
Total Current Assets		 5.25 3.22 3.64 2.28 19 15 12 15
Cash & Equivalents		 4.79 2.38 3.02 2.04 18 13 10 13
Prepaid Expenses		 0.46 0.85 0.62 0.24 1.62 1.30 1.53 1.78
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.02 0.02 0.02 0.01
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 78 82 80 80
Goodwill		 - - - - 12 12 12 12
Intangible Assets		 - - - - 66 69 68 68
Other Noncurrent Operating Assets		 - - - - 0.21 0.21 0.19 0.17
Other Noncurrent Nonoperating Assets		 - - - - - - - 0.00
Total Liabilities & Shareholders' Equity		 5.25 3.22 3.64 2.28 97 97 92 95
Total Liabilities		 0.49 0.57 0.50 1.33 14 14 15 15
Total Current Liabilities		 0.49 0.57 0.50 1.33 2.58 1.89 2.60 2.56
Accounts Payable		 0.21 0.20 0.22 0.45 1.15 0.50 0.58 0.14
Accrued Expenses		 0.28 0.37 0.28 0.88 1.38 1.33 1.96 2.35
Current Deferred Revenue		 - - - - - - - 0.01
Other Current Liabilities		 - - - - 0.05 0.05 0.05 0.06
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 12 12 12 12
Noncurrent Deferred Revenue		 - - - - - - - 0.03
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - 12 12 12 12
Other Noncurrent Operating Liabilities		 - - - - 0.14 0.13 0.12 0.09
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - - - 76 76 70 0.00
Total Equity & Noncontrolling Interests		 4.76 2.65 3.14 0.95 7.09 6.88 7.26 81
Total Preferred & Common Equity		 4.76 2.65 3.14 0.95 7.09 6.88 7.26 81
Preferred Stock		 0.00 0.00 0.00 0.00 25 25 40 0.00
Total Common Equity		 4.76 2.65 3.14 0.95 -18 -18 -33 81
Common Stock		 65 66 67 67 71 71 73 196
Retained Earnings		 -60 -63 -64 -66 -85 -89 -104 -113
Treasury Stock		 -0.30 -0.30 -0.30 -0.30 -0.30 -0.30 -0.30 -0.30
Accumulated Other Comprehensive Income / (Loss)		 - - - - -3.80 -0.27 -1.64 -1.72

Annual Metrics And Ratios for Dogwood Therapeutics

This table displays calculated financial ratios and metrics derived from Dogwood Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 8,330,390.00 18,330,390.00 19,257,937.00 1,332,178.00 2,293,162.00
DEI Adjusted Shares Outstanding		 0.00 333,216.00 733,216.00 770,317.00 1,332,178.00 2,293,162.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -47.90 -16.70 -6.88 -9.66 -15.49
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -61.08% 23.26% 55.53% -123.75% -129.27%
EBIT Growth		 0.00% -60.21% 23.26% 55.53% -125.05% -128.39%
NOPAT Growth		 0.00% -56.33% 21.26% 55.77% -124.48% -128.74%
Net Income Growth		 0.00% -54.26% 23.26% 56.76% -133.19% -177.39%
EPS Growth		 0.00% 8.57% 42.19% 56.76% -77.59% 43.05%
Operating Cash Flow Growth		 0.00% -302.79% 26.91% 57.53% -80.49% -77.67%
Free Cash Flow Firm Growth		 0.00% 0.00% 25.43% 52.43% -1,334.94% 33.29%
Invested Capital Growth		 0.00% 238.70% -40.05% 65.80% 9,989.45% 37.99%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 9.36% 16.76% 14.87% -109.29% 11.71%
EBIT Q/Q Growth		 0.00% 9.36% 16.76% 14.87% -110.50% 11.88%
NOPAT Q/Q Growth		 0.00% 12.50% 14.56% 14.87% -109.97% 11.78%
Net Income Q/Q Growth		 0.00% 11.09% 16.76% 15.09% -115.71% 10.33%
EPS Q/Q Growth		 0.00% 28.09% 36.57% 15.09% -142.64% 65.77%
Operating Cash Flow Q/Q Growth		 0.00% -22.60% 17.94% 19.80% -112.93% 13.77%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 14.32% 20.14% -1,810.23% 57.64%
Invested Capital Q/Q Growth		 0.00% 261.14% 152.43% 2,111.61% 4,633.53% 1.42%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.65%
Interest Burden Percent		 103.86% 100.00% 100.00% 97.23% 100.75% 121.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -34.56% -71.83% -112.22% -95.14% -36.28% -49.23%
Cash Return on Invested Capital (CROIC)		 0.00% -3,538.84% -2,136.87% -1,020.38% -230.36% -65.21%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -34.56% -71.83% -112.22% -95.14% 3.37% -22.91%
Return on Equity Simple (ROE_SIMPLE)		 -34.56% -110.06% -167.17% -139.12% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.00 -11 -8.62 -3.81 -8.56 -20
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -11.22% -22.88% -34.48% -28.67% -41.74% -136.35%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -100.16% 84.54% -26.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.96 -16 -12 -5.45 -12 -28
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.91 -16 -12 -5.45 -12 -28
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.75 2.94 0.59 2.91 0.00 0.13
Price to Tangible Book Value (P/TBV)		 0.75 2.94 0.59 2.91 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 58.03 0.00 15.83 1.27 0.04
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -0.99 -0.96 -0.93 -0.27 -0.15
Leverage Ratio		 1.05 1.06 1.11 1.13 1.45 1.33
Compound Leverage Factor		 1.09 1.06 1.11 1.09 1.46 1.61
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 115.75% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% -15.75% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.68 13.91 -10.69 -5.35 -1.29 -2.26
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 109.28% 53.46%
Liquidity Ratios		 - - - - - -
Current Ratio		 20.55 12.37 8.02 11.62 5.21 2.76
Quick Ratio		 19.45 10.98 6.74 9.25 4.67 2.13
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -11 -8.42 -4.01 -58 -38
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -6.25
Operating Cash Flow to Interest Expense		 -10.14 0.00 0.00 0.00 0.00 -2.55
Operating Cash Flow Less CapEx to Interest Expense		 -10.14 0.00 0.00 0.00 0.00 -2.55
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.15 0.49 0.30 0.49 49 68
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 0.35 -0.20 0.19 49 19
Enterprise Value (EV)		 -7.27 29 -2.71 7.76 63 3.01
Market Capitalization		 23 43 4.33 11 3.32 9.54
Book Value per Share		 $6.08 $1.74 $0.40 $0.20 ($7.60) $32.66
Tangible Book Value per Share		 $6.08 $1.74 $0.40 $0.20 ($65.79) ($2.83)
Total Capital		 30 15 7.33 3.81 64 75
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -30 -14 -7.03 -3.32 -15 -6.52
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.15 0.49 0.30 0.49 -1.48 -1.15
Debt-free Net Working Capital (DFNWC)		 30 15 7.33 3.81 13 5.37
Net Working Capital (NWC)		 30 15 7.33 3.81 13 5.37
Net Nonoperating Expense (NNE)		 3.34 5.01 3.63 1.48 3.79 15
Net Nonoperating Obligations (NNO)		 -30 -14 -7.03 -3.32 -15 -6.68
Total Depreciation and Amortization (D&A)		 0.05 0.00 0.00 0.00 0.07 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($1.92) ($1.11) $0.00 ($12.52) ($7.13)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 8.33M 11.07M 0.00 1.03M 4.98M
Adjusted Diluted Earnings per Share		 $0.00 ($1.92) ($1.11) $0.00 ($12.52) ($7.13)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 8.33M 11.07M 0.00 1.03M 4.98M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.33M 18.33M 0.00 1.91M 33.40M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.00 -11 -8.62 -3.81 -8.56 -20
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -25.93 0.00 0.00 0.00 0.00 -4.56
NOPAT to Interest Expense		 -18.23 0.00 0.00 0.00 0.00 -3.19
EBIT Less CapEx to Interest Expense		 -25.93 0.00 0.00 0.00 0.00 -4.56
NOPAT Less CapEx to Interest Expense		 -18.23 0.00 0.00 0.00 0.00 -3.19
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 -0.72% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.72% 0.00% 0.00% 0.00% 0.00% -0.16%

Quarterly Metrics And Ratios for Dogwood Therapeutics

This table displays calculated financial ratios and metrics derived from Dogwood Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 19,247,437.00 19,257,937.00 38,515,874.00 19,257,937.00 27,757,937.00 1,332,178.00 1,911,128.00 1,911,128.00 1,911,128.00 2,293,162.00 33,401,553.00
DEI Adjusted Shares Outstanding		 769,897.00 770,317.00 1,540,635.00 770,317.00 1,110,317.00 1,332,178.00 1,911,128.00 1,911,128.00 1,911,128.00 2,293,162.00 33,401,553.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.60 -1.43 -0.84 -1.36 -2.05 -6.19 -6.37 -1.99 -8.24 -1.65 -0.15
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 50.53% 44.33% 15.62% 27.58% -80.58% -559.18% -233.60% -264.67% -589.16% 49.38% -15.93%
EBIT Growth		 50.53% 44.33% 15.62% 27.58% -80.58% -565.39% -238.88% -266.28% -587.76% 49.85% -14.13%
NOPAT Growth		 50.84% 45.54% 15.62% 27.58% -80.58% -562.68% -237.11% -266.71% -587.00% 49.53% -14.59%
Net Income Growth		 52.05% 46.04% 14.87% 27.14% -84.66% -600.51% -746.02% -262.66% -590.35% 51.08% 54.36%
EPS Growth		 52.05% 46.04% 14.87% 27.14% -84.66% -445.58% -402.98% -73.04% -300.00% 90.52% 98.22%
Operating Cash Flow Growth		 61.32% 45.00% 44.81% -9.34% 5.24% -317.34% -399.52% -395.98% -259.59% 40.68% 2.04%
Free Cash Flow Firm Growth		 8.08% 21.68% 41.60% 45.52% 61.94% -5,370.77% -6,125.22% -8,201.65% -14,477.25% 60.45% 91.56%
Invested Capital Growth		 95.68% 65.80% 169.71% 0.00% -4,376.88% 9,989.45% 23,613.05% 59,692.28% 6,268.30% 37.99% 3.35%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 13.74% 10.69% -15.46% 18.59% -115.10% -226.02% 41.57% 11.01% -306.50% 76.05% -33.82%
EBIT Q/Q Growth		 13.74% 10.69% -15.46% 18.59% -115.10% -229.09% 41.20% 12.01% -303.89% 76.00% -33.82%
NOPAT Q/Q Growth		 13.74% 10.69% -15.46% 18.59% -115.10% -227.75% 41.26% 11.44% -302.97% 75.92% -33.37%
Net Income Q/Q Growth		 14.28% 10.68% -17.06% 18.70% -117.24% -238.84% -41.37% 65.15% -313.53% 75.99% -31.91%
EPS Q/Q Growth		 14.28% 10.68% -17.06% 18.70% -117.24% -291.22% -5.36% 76.45% -312.06% 90.73% 80.26%
Operating Cash Flow Q/Q Growth		 -29.37% -52.97% 36.19% 13.41% -12.12% -573.69% 23.63% 14.02% 18.71% -11.13% -26.12%
Free Cash Flow Firm Q/Q Growth		 9.80% 30.75% -10.27% 20.90% 36.98% -9,852.97% -25.48% -5.49% -10.65% 73.00% 73.24%
Invested Capital Q/Q Growth		 0.00% 2,111.61% -43.87% -57.95% -1,043.00% 4,633.53% 31.92% 6.02% -2.72% 1.42% -1.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 99.99% 101.78% 100.00% 99.99% 100.85% 100.02%
Interest Burden Percent		 96.92% 96.93% 98.27% 98.13% 99.11% 102.05% 241.05% 97.16% 99.49% 98.70% 98.10%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -89.19% -95.14% -138.04% -149.22% -200.48% -36.28% -51.48% -57.75% -97.54% -49.23% -34.67%
Cash Return on Invested Capital (CROIC)		 0.00% -1,020.38% -2,024.46% -6,007.21% 0.00% -230.36% -231.12% -236.12% -134.62% -65.21% -33.51%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -89.19% -95.14% -138.04% -149.22% -200.48% 3.37% 9.19% 10.10% 40.00% -22.91% -13.31%
Return on Equity Simple (ROE_SIMPLE)		 -130.99% 0.00% -191.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.89 -0.80 -0.92 -0.75 -1.61 -5.28 -3.10 -2.75 -11 -2.66 -3.55
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.71% -5.92% -10.66% -19.93% -19.63% -26.96% -78.56% -12.92% -76.90% -10.37% -9.32%
Return On Investment Capital (ROIC_SIMPLE)		 - -20.93% -34.65% -23.88% -169.66% 52.15% -43.76% -39.92% -152.47% -3.56% -4.41%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.27 -1.14 -1.31 -1.07 -2.30 -7.57 -4.45 -3.92 -16 -3.80 -5.08
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.27 -1.14 -1.31 -1.07 -2.30 -7.50 -4.38 -3.90 -16 -3.80 -5.08
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.74 2.91 3.48 1.32 4.97 0.00 0.00 0.00 0.00 0.13 0.87
Price to Tangible Book Value (P/TBV)		 3.74 2.91 3.48 1.32 4.97 0.00 0.00 0.00 0.00 0.00 117.93
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 15.83 24.90 9.69 0.00 1.27 1.42 1.39 1.71 0.04 0.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -0.93 -0.95 -0.96 -1.20 -0.27 -0.23 -0.19 -0.16 -0.15 -0.19
Leverage Ratio		 1.15 1.13 1.15 1.16 1.32 1.45 1.17 1.17 1.20 1.33 1.18
Compound Leverage Factor		 1.12 1.09 1.13 1.14 1.31 1.48 2.83 1.14 1.20 1.31 1.15
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 30.21% 30.28% 52.12% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 115.75% 91.44% 91.67% 90.62% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% -15.75% -21.64% -21.95% -42.74% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.11 -1.93 -17.89 -19.54 -41.23 -1.12 -0.77 -0.87 -1.43 -1.37 1.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 109.28% 117.86% 117.48% 141.01% 53.46% 61.61%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.77 11.62 5.66 7.27 1.71 5.21 7.43 7.80 4.49 2.76 5.86
Quick Ratio		 9.82 9.25 4.17 6.04 1.53 4.67 6.80 7.11 3.90 2.13 5.17
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.43 -0.99 -1.09 -0.86 -0.54 -54 -68 -72 -79 -21 -5.74
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -11.09 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.76 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.76 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.02 0.49 0.27 0.12 -1.09 49 65 69 67 68 67
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.54 0.19 0.17 0.12 -1.07 49 65 69 68 19 2.19
Enterprise Value (EV)		 13 7.76 6.85 1.12 2.68 63 93 96 115 3.01 57
Market Capitalization		 18 11 9.23 4.14 4.72 3.32 9.57 9.12 15 9.54 70
Book Value per Share		 $0.25 $0.20 $0.14 $0.16 $0.03 ($7.60) ($13.44) ($9.48) ($17.31) $32.66 $2.41
Tangible Book Value per Share		 $0.25 $0.20 $0.14 $0.16 $0.03 ($65.79) ($71.69) ($52.26) ($59.23) ($2.83) $0.02
Total Capital		 4.76 3.81 2.65 3.14 0.95 64 83 83 77 75 81
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.79 -3.32 -2.38 -3.02 -2.04 -15 -18 -13 -10 -6.52 -13
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.02 0.49 0.27 0.12 -1.09 -1.48 -0.96 -0.58 -1.07 -1.15 -0.78
Debt-free Net Working Capital (DFNWC)		 4.76 3.81 2.65 3.14 0.95 13 17 13 9.06 5.37 12
Net Working Capital (NWC)		 4.76 3.81 2.65 3.14 0.95 13 17 13 9.06 5.37 12
Net Nonoperating Expense (NNE)		 0.34 0.31 0.37 0.30 0.67 2.45 7.82 1.06 4.68 1.12 1.43
Net Nonoperating Obligations (NNO)		 -4.79 -3.32 -2.38 -3.02 -2.04 -15 -18 -13 -10 -6.68 -13
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.07 0.07 0.02 -0.03 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.50) ($36.75) ($1.75) ($1.25) ($2.05) ($8.02) ($8.45) ($1.99) ($8.20) ($0.76) ($0.15)
Adjusted Weighted Average Basic Shares Outstanding		 763.75K 30.04K 770.32K 916.03K 1.11M 1.03M 1.44M 1.91M 1.92M 4.98M 33.54M
Adjusted Diluted Earnings per Share		 ($1.50) ($36.75) ($1.75) ($1.25) ($2.05) ($8.02) ($8.45) ($1.99) ($8.20) ($0.76) ($0.15)
Adjusted Weighted Average Diluted Shares Outstanding		 763.75K 30.04K 770.32K 916.03K 1.11M 1.03M 1.44M 1.91M 1.92M 4.98M 33.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($36.75) $0.00 $0.00 $0.00 ($8.02) $0.00 $0.00 $0.00 ($0.76) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 770.32K 770.32K 770.32K 1.11M 1.33M 1.91M 1.91M 1.91M 2.29M 33.40M 33.63M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.89 -0.80 -0.92 -0.75 -1.61 -5.28 -3.10 -2.75 -11 -2.66 -3.55
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.73 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.51 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.73 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -0.51 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.16% -0.57%

Financials Breakdown Chart

Dogwood Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Dogwood Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Dogwood Therapeutics' net income appears to be on an upward trend, with a most recent value of -$34.26 million in 2025, rising from -$10.35 million in 2020. The previous period was -$12.35 million in 2024. See Dogwood Therapeutics' forecast for analyst expectations on what's next for the company.

Dogwood Therapeutics' total operating income in 2025 was -$27.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $27.97 million

Over the last 5 years, Dogwood Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

Dogwood Therapeutics' total liabilities were at $15.27 million at the end of 2025, a 49.1% decrease from 2024, and a 897.1% increase since 2020.

In the past 5 years, Dogwood Therapeutics' cash and equivalents has ranged from $3.32 million in 2023 to $29.80 million in 2020, and is currently $6.52 million as of their latest financial filing in 2025.

Over the last 5 years, Dogwood Therapeutics' book value per share changed from 6.08 in 2020 to 32.66 in 2025, a change of 437.5%.


Related Companies

Financial statements for NASDAQ:DWTX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel